Enalapril
Ace Inhibitors, Plain
Sold as AQUMELDI
- Drug class
- Ace Inhibitors, Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 79
Overview
Plain-language summary, compiled from the cited regulatory records
Enalapril is an active pharmaceutical ingredient classified as an ACE inhibitor [1]. It is approved for the treatment of hypertension, also known as high blood pressure [1]. Enalapril can be used alone or in combination with other medications that lower blood pressure, such as diuretics of the thiazide type [1]. When used with thiazide diuretics, the blood pressure-lowering effects are generally additive [1].
In addition to hypertension, enalapril is also indicated for the treatment of symptomatic congestive heart failure [1]. For patients with heart failure, it is typically prescribed in combination with other medications, including diuretics and digitalis [1].
Enalapril is available under various brand names [1]. The number of adverse event reports for enalapril submitted within the last 12 months is not available in the provided data [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 65 | May 29, 2026 |
| CA Canada | Health Canada | 8 | March 22, 2025 |
| US United States | FDA | 6 | February 3, 2025 |
GBUnited Kingdom· MHRA
65 products
Uses
1)
How to take
CACanada· Health Canada
8 products
Uses
ENALAPRIL (enalapril maleate) is indicated for: essential or renovascular hypertension treatment of symptomatic congestive heart failure Hypertension ENALAPRIL is indicated in the treatment of essential or renovascular hypertension.
It is usually administered in association with other drugs, particularly thiazide diuretics. In using ENALAPRIL consideration should be given to the risk of angioedema (see 7 WARNINGS AND PRECAUTIONS). Congestive Heart Failure ENALAPRIL is indicated in the treatment of symptomatic congestive heart failure usually in combination with diuretics and/or digitalis.
In these patients, enalapril improves symptoms, increases survival, and decreases the frequency of hospitalization (see 14 CLINICAL TRIALS for details and limitations of survival trials). Treatment with ENALAPRIL should be initiated under close medical supervision.
In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35%), enalapril decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see 14 CLINICAL TRIALS for details and limitations of survival trials).
USUnited States· FDA
6 products
Uses
INDICATIONS AND USAGE
Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive.
Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials).
Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials).
Drug interactions
Known interactions involving Enalapril. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL179070268 · revised May 29, 2026
- [2]Health Canada (DPD) · 02400650 · revised March 22, 2025
- [3]FDA DailyMed · 0b3dbe11-ff75-cb… · revised February 3, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.